Related content

Safety and efficacy of interferon-α in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy

By Arimura Kimiyoshi   Nakagawa Masanori   Izumo Shuji   Usuku Koichiro   Itoyama Yasuto   Kira Jun-ichi   Osame Mitsuhiro  

Journal of NeuroVirology, Vol. 13, Iss. 4, 2007-07 ,pp. : 364-372

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

By Polman C.  

Journal of Neurology, Vol. 255, Iss. 4, 2008-04 ,pp. : 480-487

Springer Publishing Company

Access to resources Recommend Favorite

The Efficacy and Tolerability of Duloxetine in the Treatment of Anxious Versus Non-Anxious Depression: A Post-Hoc Analysis of an Open-Label Outpatient Study

By Fava Maurizio   Martinez James M.   Greist John   Marangell Lauren B.   Brown Eileen   Chen Lei   Wohlreich Madelaine M.  

Annals of Clinical Psychiatry (after Jan 1, 2004), Vol. 19, Iss. 3, 2007-07 ,pp. : 187-195

Informa Healthcare

Access to resources Recommend Favorite

Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b

By Minagar Alireza   Ma Wanlong   Zhang Xi   Wang Xiuqiang   Zhang Ke   Alexander J Steven   Gonzalez-Toledo Eduardo   Albitar Maher  

Neurological Research, Vol. 34, Iss. 6, 2012-07 ,pp. : 611-618

Maney Publishing

Access to resources Recommend Favorite

T 1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment

By Pozzilli C.  

Brain, Vol. 124, Iss. 7, 2001-07 ,pp. : 1396-1402

Oxford University Press

Access to resources Recommend Favorite